Year-end Sale % OFF 
Abstract
To the Editor: The emergency conditions imposed by the coronavirus disease 2019 (COVID-19)1 pandemic have forced drug regulatory agencies, from the Food and Drug Administration to the European Medicines Agency, to allow the use of drugs that are not tested and approved for this precise condition. Severe cutaneous adverse drug reactions2 are rare, ranging from 5 cases per million of acute generalized exanthematous pustulosis and drug reaction with eosinophilia systemic symptoms to 1 case per million of toxic epidermal necrolysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
